Ivizon Max 2.0 for Diabetic Retinopathy
Natural health product licensed in Canada
If this product were sold in France
- Dose déclarée au-delà d'une limite
Vitamine C: up to 500 mg a day according to the dosing instructions published by Health Canada (4 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 180 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Dose déclarée au-delà d'une limite
Zinc: up to 20 mg a day according to the dosing instructions published by Health Canada (4 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 15 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Vitamine C Source : Acide ascorbique | 125 milligramme | 500,000 µg |
| Vitamine E Source : Succinate d'acide de d-alpha tocophéryle | 67 mg AT | Not calculated |
| Zinc Source : Picolinate de zinc | 5 milligramme | 20,000 µg |
| Chrome Source : Picolinate de chrome (III) | 125 microgrammes | Not calculated |
| Cuivre Source : Diglycinate de cuivre (II) | 0.5 milligramme | 2,000 µg |
| Sélénium Source : Sélénométhionine | 12.5 microgrammes | Not calculated |
| Lutéine Source : Lutéine | 2.5 milligramme | Not calculated |
| (3R,3'R)-bêta,bêta-Carotène-3,3'-diol Source : Zeaxanthin | 0.5 milligramme | Not calculated |
| (3R,3'S)-b,b-Carotene-3,3'-diol Source : Meso-Zeaxanthin | 2.5 milligramme | Not calculated |
| Vaccinium myrtillus Source : Fruit Extract : Matériel brut sec Extraction ratio : 100:1 Dry plant equivalent : 3,000 milligramme Potency : 10.8 milligramme Anthocyanidins | 30 milligramme | Not calculated |
| Pinus pinaster Source : Écorce (tige) Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 150 milligramme Potency : 28.125 milligramme Procyanidins | 37.5 milligramme | Not calculated |
| Thiamine Source : Benfotiamine | 25 milligramme | 100,000 µg |
| 3,3',4',5,7-Pentahydroxyflavone-3-rutinoside Source : Rutine | 6.25 milligramme | Not calculated |
Non-medicinal ingredients
Hypromellose, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Capsule | 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Antioxidant for the maintenance of eye health. Used in Herbal Medicine to help slow the progression of disorders of the eye, such as diabetic and hypertensive retinopathy, and macular degeneration. Provides support for healthy glucose metabolism.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Product record
- Licence holder
- 2201371 Ontario Inc.
- NPN or DIN-HM
- 80073843
- Status
- Inactive licence
- Licence date
- 17 November 2016
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80073843
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Vaccinium myrtillus
Read the warning, when it applies and the studies cited
BILBERRY - VACCINIUM MYRTILLUS - Buccal
Route of administration: Buccal (Blumenthal et al. 2000)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 30 January 2026
BILBERRY - VACCINIUM MYRTILLUS - Oral
Route of administration: Oral (Blumenthal et al. 2000)
Cautions and warnings
Condition of application: Relief of diarrhea.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Ivizon Max 2.0 for Diabetic Retinopathy”, https://compoatlas.com/en/supplements/canada/80073843-ivizon-max-2-0-for-diabetic-retinopathy, updated 17 November 2016.